Efroze Chemical Industries (Pvt.) Ltd. - Pharma Division

Efroze Chemicals Industries (Private) Ltd. came into existence in 1968 with the Dedication to the Quality Pharmaceuticals, to empower mankind by promoting mental and physical wellbeing around the globe. Globally - The international footprint extends to 20 countries embracing different locales and cultures of CIS, Africa and Far East Asia.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CVS PHARMACY IS TESTING SELF-DRIVING VEHICLES FOR MEDICATION DELIVERY

Fiercehealthcare | June 02, 2020

news image

CVS Health began testing drone delivery last year. Now, the company is moving on to try self-driving vehicles. The pharmacy retail giant is working with autonomous vehicle startup Nuro to test prescription delivery in the Houston market. Nuro, which was founded by two ex-Google engineers, will use its fleet of autonomous vehicles to deliver prescriptions and essentials to CVS Pharmacy customers. The deliveries will start this month and will come at no extra charge to CVS customers in Houston. &l...

Read More

PHARMACY MARKET

AVACTA ANNOUNCES FDA APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR AVA6000

Avacta | November 29, 2021

news image

Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase I clinical trial, ALS-6000-101, into clinical trial sites in the United States. AVA6000 is a novel f...

Read More

JUDGE WIPES OUT BIOGEN'S TECFIDERA PATENT PROTECTIONS IN SUIT AGAINST MYLAN

Fiercepharma | June 18, 2020

news image

In the high-stakes patent fight between Biogen and Mylan over Tecfidera’s main remaining patent, Mylan has scored a major win in federal court. U.S. District Judge Irene Keeley said Mylan “demonstrated by clear and convincing evidence” that certain claims of Biogen’s '514 patent are invalid for “lack of written description.” The decision threatens Biogen’s bestselling medicine with early generics; Tecfidera, a multiple sclerosis drug, generated $3.3 ...

Read More

ACERUS ANNOUNCES PRIVATE PLACEMENT AND REFINANCING TRANSACTIONS

BioSpace | February 13, 2020

news image

Acerus Pharmaceuticals Corporation Today announced that it has entered into agreements with First Generation Capital, Inc. (“First Generation”) in respect of an equity financing and debt-to-equity conversion by First Generation and with SWK Funding LLC (“SWK”) in respect of an amendment to the Company’s existing credit facility (the “SWK Facility”) with SWK (the “Refinancing Transactions”). First Generation is currently the Company’s la...

Read More
news image

CVS PHARMACY IS TESTING SELF-DRIVING VEHICLES FOR MEDICATION DELIVERY

Fiercehealthcare | June 02, 2020

CVS Health began testing drone delivery last year. Now, the company is moving on to try self-driving vehicles. The pharmacy retail giant is working with autonomous vehicle startup Nuro to test prescription delivery in the Houston market. Nuro, which was founded by two ex-Google engineers, will use its fleet of autonomous vehicles to deliver prescriptions and essentials to CVS Pharmacy customers. The deliveries will start this month and will come at no extra charge to CVS customers in Houston. &l...

Read More
news image

PHARMACY MARKET

AVACTA ANNOUNCES FDA APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR AVA6000

Avacta | November 29, 2021

Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase I clinical trial, ALS-6000-101, into clinical trial sites in the United States. AVA6000 is a novel f...

Read More
news image

JUDGE WIPES OUT BIOGEN'S TECFIDERA PATENT PROTECTIONS IN SUIT AGAINST MYLAN

Fiercepharma | June 18, 2020

In the high-stakes patent fight between Biogen and Mylan over Tecfidera’s main remaining patent, Mylan has scored a major win in federal court. U.S. District Judge Irene Keeley said Mylan “demonstrated by clear and convincing evidence” that certain claims of Biogen’s '514 patent are invalid for “lack of written description.” The decision threatens Biogen’s bestselling medicine with early generics; Tecfidera, a multiple sclerosis drug, generated $3.3 ...

Read More
news image

ACERUS ANNOUNCES PRIVATE PLACEMENT AND REFINANCING TRANSACTIONS

BioSpace | February 13, 2020

Acerus Pharmaceuticals Corporation Today announced that it has entered into agreements with First Generation Capital, Inc. (“First Generation”) in respect of an equity financing and debt-to-equity conversion by First Generation and with SWK Funding LLC (“SWK”) in respect of an amendment to the Company’s existing credit facility (the “SWK Facility”) with SWK (the “Refinancing Transactions”). First Generation is currently the Company’s la...

Read More